Advanced Heart Failure Clinical Trial
— LAICAOfficial title:
Double-blind Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of Intermittent, Long-term Administration of Levosimendan in Patients With Advanced Heart Failure
Verified date | September 2013 |
Source | Hospital Universitario de Canarias |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Spanish Agency of Medicines |
Study type | Interventional |
The purpose of this study is to determine whether the treatment strategy of long-term intermittent every 30 days, continuous intravenous infusion for 24 hours of Levosimendan, associated to optimal contemporary treatment for advanced heart failure reduce the incidence of admission for heart failure worsening at 12 months follow up, compared with the strategy based solely in the optimal contemporary treatment for advanced heart failure.
Status | Enrolling by invitation |
Enrollment | 213 |
Est. completion date | December 2014 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age over 18 - Severe symptoms of heart failure with dyspnea and/or fatigue at rest or minimal effort (functional class III and IV of NYHA) - Episodes of fluid retention (pulmonary or systemic venous congestion, peripheral edema) and/or low cardiac output at rest (peripheral hypoperfusion) - objective evidence of severe cardiac dysfunction determined by the presence of at least one of the following: - Left ventricular ejection fraction </= 30% - A severe impairment of cardiac function by echocardiography with Doppler transmitral flow pattern pseudonormal or restrictive. - A left ventricular filling pressure elevated (PCP> 16 mmHg and / or DBP average> 12 mm Hg for pulmonary artery catheterization) - Levels of BNP or NT-proBNP higher in the absence of noncardiac causes for this. - Severe impairment of functional capacity as evidenced by one of the following: - Inability to exercise - A distance <300 m or less in women and / or patients >/= 75 years in the 6-minute walk test - A test of myocardial oxygen consumption <12-14 ml / kg / min. - >/= 1 prior history of HF hospitalization in the previous 6 months - Presence of all the above criteria despite attempts to optimize therapy including diuretics, inhibitors of the renin-angiotensin-aldosterone system and beta-blockers, unless these drugs were not tolerated or were contraindicated, and cardiac resynchronization therapy when indicated. - consent to participate in the study. Exclusion Criteria: - Levosimendan allergy or hypersensitivity. - Severe renal impairment (creatinine clearance <30 ml / min). - Severe liver impairment. - History of autoimmune disease. - Pregnancy. - Women of childbearing age not using adequate contraception (hormonal, IUD, barrier + spermicide) - Heart disease with significant obstructions to ventricular filling or emptying. - Severe hypotension (Systolic < 90 mmHg). - Tachycardia > 120 bpm or a history of torsion point type ventricular tachycardia. - Severe concomitant disease with decreased short-term prognosis. - Inability to give informed consent. - Participation in another study. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Department of Cardiology. Hospital Universitario de Canarias | La Laguna | S.C. de Tenerife |
Lead Sponsor | Collaborator |
---|---|
Hospital Universitario de Canarias |
Spain,
García-González MJ, de Mora-Martín M, López-Fernández S, López-Díaz J, Martínez-Sellés M, Romero-García J, Cordero M, Lara-Padrón A, Marrero-Rodríguez F, del Mar García-Saiz M, Aldea-Perona A; LAICA study investigators. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study. Cardiovasc Drugs Ther. 2013 Dec;27(6):573-9. doi: 10.1007/s10557-013-6476-7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the incidence of admission for heart failure worsening in patients with advanced heart failure, defined as first admission to emergency services or hospitalization more than 12 hours due to a heart failure worsening. | one year | Yes | |
Secondary | Time from randomization until first hospitalization for heart failure worsening. All-cause mortality. Major cardiac events. Serious adverse events. Changes in NYHA scale and quality of life of patients. To analyze the cost-effectiveness of treatment. | one year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT02962973 -
European Clinical Evaluation of the Carmat Total Artificial Heart
|
N/A | |
Recruiting |
NCT04915924 -
Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea
|
N/A | |
Completed |
NCT01626404 -
Screening for Advanced Heart Failure Treatment (SEE-HF)
|
||
Withdrawn |
NCT00572286 -
Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study
|
N/A | |
Completed |
NCT00690157 -
Registry of Patients Referred for Heart Transplantation
|
N/A | |
Active, not recruiting |
NCT03874312 -
Ultrasound-assessed Internal Jugular Vein Distensibility in Advanced Chronic Heart Failure (US-IJVD in CHF)
|
||
Recruiting |
NCT05284955 -
Screening for Advanced Heart Failure IN Stable outPatientS - The SAINTS Study (SAINTS B)
|
Phase 4 | |
Completed |
NCT01643551 -
Neuron Specific Enolase in Ventricular Assist Device Recipients
|
N/A | |
Terminated |
NCT04703855 -
Hong Kong and Taiwan HM3 PMS
|
N/A | |
Suspended |
NCT04851236 -
Pilot Study of Massage Therapy to Improve Self Efficacy in Patients With Left-ventricular Device
|
Early Phase 1 | |
Recruiting |
NCT03526627 -
Advanced Care Management in Patients With Advanced Heart Failure
|
||
Recruiting |
NCT06228209 -
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
|
N/A | |
Active, not recruiting |
NCT06259045 -
Cardiac Cachexia in Advanced Heart Failure
|
||
Recruiting |
NCT05271214 -
Conservative Management of Left Ventricular Assist Device Candidates
|
||
Recruiting |
NCT04475393 -
Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure
|
N/A | |
Recruiting |
NCT03919136 -
Wrist Worn Blood Pressure Measurement
|
||
Recruiting |
NCT03911349 -
Wrist Worn Blood Pressure Measurement
|
N/A | |
Completed |
NCT01210573 -
Prospective Observation of Exercise Parameters in Advanced Heart Failure
|
N/A | |
Recruiting |
NCT04423562 -
PROgnostic Value of Exercise Capacity Measured as Peak Oxygen Uptake (pVO2) in Recipients of Left Ventricular Assist Devices
|